Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.

ABSTRACT:

Aims

A non-invasive gene-expression profiling (GEP) test for rejection surveillance of heart transplant recipients originated in the USA. A European-based study, Cardiac Allograft Rejection Gene Expression Observational II Study (CARGO II), was conducted to further clinically validate the GEP test performance.

Methods and results

Blood samples for GEP testing (AlloMap(®), CareDx, Brisbane, CA, USA) were collected during post-transplant surveillance. The reference standard for rejection status was based on histopathology grading of tissue from endomyocardial biopsy. The area under the receiver operating characteristic curve (AUC-ROC), negative (NPVs), and positive predictive values (PPVs) for the GEP scores (range 0-39) were computed. Considering the GEP score of 34 as a cut-

SUBMITTER: Crespo-Leiro MG 

PROVIDER: S-EPMC5015661 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature